Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray

Modern Pathology

Volumn 16, Issue 9, 2003, Pages 937-943

  Park, Kyeongmee ^a   Kim, Jungyeon ^a   Lim, Sungjig ^a   Han, Sehwan ^a   Lee, Jung Young ^b  

^a Inje University College of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Breast carcinoma; Chromogenic in situ hybridization; Fluorescence in situ hybridization; HER2 neu; Tissue microarray

Indexed keywords

ANALYTIC METHOD; ARTICLE; BREAST; BREAST CARCINOMA; CHROMOGENIC IN SITU HYBRIDIZATION; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; COST; DIAGNOSTIC ACCURACY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE TECHNOLOGY; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NUCLEAR PLEOMORPHISM; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; STATISTICAL ANALYSIS; TISSUE MICROARRAY; VALIDATION PROCESS;

BREAST NEOPLASMS; HUMANS; IN SITU HYBRIDIZATION; PROGNOSIS; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 0141853741     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MP.0000086487.78558.7D     Document Type: Article

References (22)

1. Stern DF, Heffernan PA, Weinberg RA. p185, a product of the neu proto-oncogene, is a receptor-like protein associated with tyrosine kinase activity. Mol Cell Biol 1986;6:1729-40.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WJ. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
3. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990;8:103-12.
4. Toikkanen S, Helin H, Isola J, Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer. A 30-yr follow-up. J Clin Oncol 1992;10:1044-8.
5. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90:1361-70.
6. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-6.
7. Kallioniemi OP, Kallioniemi A, Kurisu W, Thor A, Chen LG, Smith HS, et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci U S A 1992;89:5321-5.
8. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15:2894-904.
9. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positive do not get the message. J Clin Oncol 2001;19:2714-21.
10. Tanner M, Gancberg D, Di Leo A, Lasimont D, Rouas G, Piccart M, et al. Chromogenic in situ hybridization. A practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000;157:1467-72.
11. DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, et al. Use of a cDNA microarray to analyze gene expression patterns in human cancer. Nat Genet 1996;14:457-60.
12. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
13. Kallioniemi OP, Wagner U, Kononen J, Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001;10:657-62.
14. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer: I. The value of histologic grade in breast cancer - experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
15. Black MM, Speeder FD. Nuclear structure in cancer tissue. Surg Gynecol 1957;105:97-102.
16. Bucher C, Torhorst J, Bubendorf L, Schraml P, Kononen J, Moch H, et al. Tissue microarrays ("tissue chips") for high-throughput cancer genetics: Linking molecular changes to clinical endpoints. Am J Hum Genet 1999;65(Suppl):43.
17. Gillett CE, Springall RJ, Barnes DM, Hanby AM. Multiple tissue core arrays in histopathology research: a validation study. J Pathol 2000;192:549-53.
18. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000;80:1943-9.
19. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996;13:63-72.
20. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-7.
21. Roche PC, Ingle JN. Increased Her-2 with US Food and Drug Administration approved antibody. J Clin Oncol 1999;17:434-5.
22. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determining Her-2/neu status of breast cancer using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999;17:1983-7.